评估三种类药物对控制Trypanosoma evansi evansi的疗效
Somaia Abouakkada1, Nadia Labn1, Safeya Henidy1
1Department of Parasitology, Faculty of Veterinary Medicine, Alexandria University, Egypt.
Veterinary parasitology
|December 3, 2025
概括
梅拉萨明化和迪米纳乙酸盐在较高剂量的小鼠中显示出对Trypanosoma evansi的效果有所改善,但 Pyramine是无效的. 在所有治疗组中都观察到复发和组织损伤,突出显示了治疗挑战.
科学领域:
- 兽医寄生虫学 兽医寄生虫学
- 动物传播疾病 动物传播疾病
- 药物疗效研究 药物疗效研究
背景情况:
- 特里帕诺索马埃文西 (Trypanosoma evansi) 构成了严重的动物性传染病威胁,对经济和健康产生影响.
- 有限有效的治疗方法和日益增长的耐药性需要新的治疗策略.
研究的目的:
- 评估皮拉胺,梅拉萨明化和迪米纳酸盐对小鼠Trypanosoma evansi的治疗疗效.
- 根据寄生素,复发,临床症状和病理发现来评估药物的有效性.
主要方法:
- 72只瑞士白色老鼠被感染了Trypanosoma evansi,并用不同剂量的皮拉胺,米拉萨明化和迪米纳乙酸盐治疗.
- 通过对寄生病的监测,体重,血液学,生化学和组织病理学来评估有效性.
主要成果:
- 在测试的两种剂量中,皮拉胺是无效的.
- 较高剂量的麦拉萨明化和迪米纳乙酸盐提高了疗效,但没有防止复发.
- 感染导致贫血,白细胞病变,乙,蛋白质水平降低,观察到多个器官的组织损伤.
结论:
- 较高剂量的麦拉萨明化显示出治疗Trypanosoma evansi感染的潜力,尽管存在复发的挑战.
- 需要进一步的研究来克服耐药性并实现持续的寄生虫清除.
相关概念视频
American Trypanosomiasis
Chagas disease, or American trypanosomiasis, is a vector-borne parasitic infection caused by Trypanosoma cruzi, a flagellated protozoan (kinetoplastid) of the family Trypanosomatidae. The disease is endemic in Latin America, although cases are increasingly reported worldwide due to human migration. Transmission most commonly occurs when feces of infected triatomine bugs contaminate bite wounds or mucosal surfaces; additional routes include congenital, transfusional, transplant-related, and oral...
Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...


